Positive Phase II stroke data

ReNeuron has presented positive Phase II trial data for its CTX cells in chronic stroke patients. Reported data included 15 out of 21 patients having a clinically relevant and sustained response on at least one efficacy measure. This confirms the potential for long-term benefits from treatment with its CTX neural stem cells and has led to the decision to progress to a pivotal controlled clinical study in 2017. Beyond CTX, we expect safety and efficacy data from its retinitis pigmentosa (RP) trial in 2017. Our rNPV has increased to £278m (vs £249m) as we have increased the probability of the stroke programme’s success to 25% (from 20%) and updated cash.